Helicobacter pylori infection remains highly prevalent, and the effectiveness of standard triple therapy has declined due to increasing clarithromycin resistance in Thailand and many Asian regions. Although Vonoprazan based dual therapy has shown high eradication rates, its clinical use is limited by cost and lack of availability within the national essential drug list. High-dose omeprazole and Amoxicillin therapy with added Bismuth may offer a similarly effective but more accessible alternative
Conditions
Interventions
Omeprazole 40 mg BID plus Amoxicillin 1 g TID plus Bismuth 1048 mg BID for 14 days.,Vonoprazan 20 mg BID plus Amoxicillin 1 g TID for 14 days.
Experimental Drug,Experimental Drug
High dose Omeprazole-Amoxicillin plus Bismuth,Vonoprazan-Amoxicillin dual therapy
Sponsors
Department of internal medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Confirmed H. pylori infection by histology, rapid urease test, urea breath test, or stool antigen test 2. No prior eradication therapy
Exclusion criteria
Exclusion criteria: 1. History of previous Helicobacter pylori treatment 2. History of chronic and severe underlying diseases, such as liver disease, chronic renal failure, or advanced malignancy 3. History of gastric cancer 4. History of allergy to any study medications, including Penicillin or Salicylate group drugs 5. Pregnant or breastfeeding women 6. History of using medications that may interact with the study drugs, such as Clopidogrel or Warfarin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication 6 weeks post-treatment. 6 weeks Stool antigen test or urea breath test | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events during treatment 2 weeks clinical,Medication adherence during treatment 2 weeks percent of medication adherence | — |
Countries
Thailand
Contacts
Public Contactpornrawin krathong
Rajavithi hospital
Outcome results
None listed